The role of in vitro diagnostic companies in reducing laboratory error

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 6, 2007, Pages 781-788

  Stankovic, Ana K ^a,b   Romeo, Peter ^b  

^a Preanalytical Systems   (United States)

^b BD Technologies   (United States)

Author keywords

Define Measure Analyze Improve Control (DMAIC); Design for Six Sigma; Evacuated tubes; In vitro diagnostic (IVD) products; Laboratory errors; New Product Development; Patient safety; Preanalytical variables; Product development; Six Sigma

Indexed keywords

ANALYTICAL ERROR; BLOOD SAMPLING; CLINICAL LABORATORY; DIAGNOSTIC PROCEDURE; HEALTH CARE PERSONNEL; HUMAN; IN VITRO STUDY; LABORATORY DIAGNOSIS; LIFE CYCLE; METHODOLOGY; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT;

DIAGNOSTIC ERRORS; HUMANS; INDUSTRY; QUALITY ASSURANCE, HEALTH CARE; REAGENT KITS, DIAGNOSTIC;

EID: 34250770039     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.175     Document Type: Review

References (13)

1. Bonini P, Plebani M, Ceriotti F, Rubboli F. Errors in laboratory medicine. Clin Chem 2002;48:691-8.
2. Nutting PA, Main DS, Fischer PM, Stull TM, Pontious M, Boone DJ, et al. Towards optimal laboratory use. Problems in laboratory testing in primary care. J Am Med Assoc 1996;275:635-9.
3. Ross JW, Boone DJ. Assessing the effect of mistakes in the total testing process on the quality of patient care. In: Martin L, Wagner W, Essien JD, editors. Proceedings of the 1989 Institute on Critical Issues in Health Laboratory Practice. Minneapolis, MN: DuPont Press, 1991: Abstract 102.
4. US Code of Federal Regulations, Title 21, vol 8, section 809.3, 2006. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?fr=809.3. Accessed March 24, 2007.
5. Federal Food, Drug, and Cosmetic Act, section 210(h), 2004. Available at http://www.fda.gov/opacom/laws/fdcact/fdcact1.htm. Accessed March 24, 2007.
6. Public Health Service Act, section 351. Available at http://www.fda.gov/ opacom/laws/phsvcact/phsvcact.htm. Accessed March 24, 2007.
7. US Code of Federal Regulations, Title 21, vol 8, subpart C, section 820.30, 2006. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm?CFRPart=820&showFR=1. Accessed March 24, 2007.
8. ISO standard 14971:2000 Application of risk management to medical devices. Geneva: ISO.
9. Cooper RG. The new product process - the game plan. In: Winning at new products: accelerating the process from idea to launch, 2nd ed. Reading: Addison-Wesley, 1993:95-120.
10. Creveling CM, Slusky JL, Antis D Jr. Product design using design for Six Sigma. In: Design for Six Sigma in technology and product development, 1st ed. Upper Saddle River, NJ: Pearson Education Inc, 2002:111-76.
11. Pruett JM, Schneider H. In: Essentials of SPC in the process industries, 1st ed. Research Triangle Park, NC: Instrument Society of America, 1993:245-62.
12. Glendenning P, Musk AA, Taranto M, Vasikaran SD. Preanalytical factors in the measurement of intact parathyroid hormone with the DPC IMMULITE assay. Clin Chem 2002;48:567-8.
13. Adcock DM, Kressin DC, Marlar RA. Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration. Am J Clin Pathol 1998;109:595-9.